Lipolytic Effects of a Novel GH Fragment (AOD9604) in Laboratory Models. Hormone and Metabolic Research.
Regulatory Considerations: Depending on the nature and location of your research in 2026, different regulatory bodies might have specific guidelines regarding the administration of research compounds
The medication is formulated in various strengths and vial sizes to accommodate physician determinations of patient need
Unlike the full-length growth hormone, AOD9604 retains the lipolytic (fat-mobilizing) and anti-lipogenic (fat-inhibiting) properties of hGH, while importantly lacking its proliferative effects (e.g., on glucose levels, IGF-1 production, or cell proliferation)
The few who are not, are those who have pacemakers (AICDs), and those who have had dermal fillers in the treatment area (under the eye) within the past 2 weeks